Related Experiment Video
Updated: May 29, 2026

A Modified Method for Heterotopic Mouse Heart Transplantion
Published on: June 23, 2014
Should heart transplant recipients with early graft failure be considered for retransplantation?
Alexander Iribarne1, Kimberly N Hong, Rachel Easterwood
1University of Chicago Medical Center, Center for Health & the Social Sciences, The University of Chicago, Chicago, IL 60637, USA.
Insights
Retransplantation within 90 days of initial heart transplant (re-Tx) does not increase risks after adjusting for patient factors. However, careful consideration of re-Tx indications is crucial due to patient comorbidities.
Area of Science:
- Cardiology
- Transplant Surgery
- Outcomes Research
Background:
- Orthotopic heart transplantation is a life-saving procedure.
- Retransplantation (re-Tx) is sometimes necessary when the initial graft fails.
- The optimal timing and outcomes of early re-Tx remain debated.
Purpose of the Study:
- To determine if retransplantation within 90 days of a primary heart transplant is associated with inferior outcomes.
- To compare outcomes of early re-Tx recipients with primary heart transplant recipients (controls).
Main Methods:
- Utilized de-identified data from the United Network for Organ Sharing (1995-2008).
- Included 26,804 adult heart transplant recipients.
- Employed multivariable regression to assess risk factors for posttransplant graft failure (PTGF) at 90 days.
Main Results:
- 90 (0.34%) patients underwent re-Tx within 90 days.
- Unadjusted outcomes (PTGF, infection, dialysis, primary nonfunction) were higher in the re-Tx group.
- After risk adjustment, PTGF, infection, dialysis, stroke, and primary nonfunction did not differ significantly between re-Tx and control groups.
Conclusions:
- Early retransplantation (within 90 days) is not independently associated with increased morbidity or mortality when controlling for recipient characteristics.
- Unadjusted survival was worse in the re-Tx group, highlighting significant underlying patient comorbidities.
- Indications for early retransplantation are rare and require critical evaluation despite similar adjusted outcomes.
Background:
The purpose of this study was to determine if orthotopic heart transplantation performed within 90 days of an initial heart transplant (re-Tx) should be a contraindication to retransplantation based on inferior outcomes when compared with primary orthotopic heart transplantation recipients (control).
Methods:
De-identified data were obtained from the United Network for Organ Sharing. The study population included all adult heart transplant recipients greater than 18 years old from 1995 to 2008 (n=26,804). Multivariable regression was performed in order to assess the simultaneous effect of multiple risk factors on posttransplant graft failure (PTGF) at 90 days. Secondary outcomes of interest included infection, stroke, and dialysis during the transplant hospitalization as well as primary nonfunction of the graft at 90 days.
Results:
Among the study cohort, there were 90 (0.34%) re-Tx patients. Median survival in this group was 1.6 years compared with 10.5 years for controls. Unadjusted PTGF, infection, dialysis, and primary nonfunction were significantly higher (p<0.001) in the re-Tx group. After risk adjustment, however, PTGF (p=0.545), infection (p=0.696), dialysis (p=0.664), stroke (p=0.115), and primary nonfunction (p=0.531), did not differ significantly between the 2 groups.
Conclusions:
When controlling for pretransplant recipient characteristics, retransplantation within 90 days of a previous transplant is not associated with increased morbidity or mortality. However, unadjusted overall survival was significantly worse in the re-Tx group. This suggests that although retransplantation at 90 days alone is not a risk factor for inferior outcomes, given the significant comorbidities of these patients, the indications for retransplantation within 90 days are rare and must be critically examined.
Related Concept Videos
Kidney Transplant I: Introduction
Kidney Transplant II: Surgical Procedure
Tissue Transplantation
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
Kidney Transplant III: Nursing Management

